Bruce Fireman to Confounding Factors (Epidemiology)
This is a "connection" page, showing publications Bruce Fireman has written about Confounding Factors (Epidemiology).
Connection Strength
0.982
-
Evaluation of propensity scores, disease risk scores, and regression in confounder adjustment for the safety of emerging treatment with group sequential monitoring. Pharmacoepidemiol Drug Saf. 2016 Apr; 25(4):453-61.
Score: 0.525
-
Confounding adjustment in comparative effectiveness research conducted within distributed research networks. Med Care. 2013 Aug; 51(8 Suppl 3):S4-10.
Score: 0.110
-
A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent. Pharmacoepidemiol Drug Saf. 2012 Jan; 21 Suppl 1:282-90.
Score: 0.099
-
Statins and Reduced Risk of Liver Cancer: Evidence for Confounding. J Natl Cancer Inst. 2016 10; 108(10).
Score: 0.034
-
Network meta-analysis incorporating randomized controlled trials and non-randomized comparative cohort studies for assessing the safety and effectiveness of medical treatments: challenges and opportunities. Syst Rev. 2015 Nov 05; 4:147.
Score: 0.032
-
Targeted maximum likelihood estimation in safety analysis. J Clin Epidemiol. 2013 Aug; 66(8 Suppl):S91-8.
Score: 0.028
-
Super learning to hedge against incorrect inference from arbitrary parametric assumptions in marginal structural modeling. J Clin Epidemiol. 2013 Aug; 66(8 Suppl):S99-109.
Score: 0.028
-
Multivariable confounding adjustment in distributed data networks without sharing of patient-level data. Pharmacoepidemiol Drug Saf. 2013 Nov; 22(11):1171-7.
Score: 0.027
-
Dynamic marginal structural modeling to evaluate the comparative effectiveness of more or less aggressive treatment intensification strategies in adults with type 2 diabetes. Pharmacoepidemiol Drug Saf. 2012 May; 21 Suppl 2:99-113.
Score: 0.025
-
Design considerations in an active medical product safety monitoring system. Pharmacoepidemiol Drug Saf. 2012 Jan; 21 Suppl 1:32-40.
Score: 0.025
-
When should case-only designs be used for safety monitoring of medical products? Pharmacoepidemiol Drug Saf. 2012 Jan; 21 Suppl 1:50-61.
Score: 0.025
-
Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data. Pharmacoepidemiol Drug Saf. 2012 Jan; 21 Suppl 1:62-71.
Score: 0.025